Literature DB >> 16642425

Ferrus calcium citrate is absorbed better than iron bisglycinate in patients with Crohn's disease, but not in healthy controls.

Irit Chermesh1, Ada Tamir, Alain Suissa, Rami Eliakim.   

Abstract

Our purpose was to compare the absorption of iron bisglycinate and ferrous calcium citrate in volunteers using an oral iron tolerance test. Twenty volunteers, 10 healthy controls and 10 with stable Crohn's disease, agreed to participate in the study. All were given 50 mg of elemental iron as iron bisglycinate or ferrous calcium citrate. Serum iron levels were monitored for 4 hr. After a week, each received the other regimen. Using the area under the curve as indicator, the oral iron absorption test revealed that absorption of iron post-ingestion of ferrous calcium citrate was better than after ingestion of iron bisglycinate for the group as a whole (P < 0.03). Volunteers with Crohn's disease absorbed ferrous calcium citrate better than iron bisglycinate (P=0.005). No difference was noted in the absorption of either preparation by healthy volunteers. Ferrus calcium citrate is apparently more effective than iron bisglycinate in patients with Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642425     DOI: 10.1007/s10620-005-9036-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

Review 1.  The absorption and metabolism of iron amino acid chelate.

Authors:  H D Ashmead
Journal:  Arch Latinoam Nutr       Date:  2001-03

2.  Intravenous iron in a primary-care clinic.

Authors:  I Maslovsky
Journal:  Am J Hematol       Date:  2005-04       Impact factor: 10.047

3.  Absorption of controlled-release iron.

Authors:  J D Cook; D A Lipschitz; B S Skikne
Journal:  Clin Pharmacol Ther       Date:  1982-10       Impact factor: 6.875

4.  Effect of dose and formulation on iron tolerance in pregnancy.

Authors:  V Shatrugna; L Raman; U Kailash; N Balakrishna; K V Rao
Journal:  Natl Med J India       Date:  1999 Jan-Feb       Impact factor: 0.537

5.  Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy.

Authors:  Anupama D de Silva; Maria Mylonaki; David S Rampton
Journal:  Inflamm Bowel Dis       Date:  2003-09       Impact factor: 5.325

Review 6.  Iron, anaemia, and inflammatory bowel diseases.

Authors:  C Gasche; M C E Lomer; I Cavill; G Weiss
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 7.  Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature.

Authors:  Alisa Wilson; Eileen Reyes; Josh Ofman
Journal:  Am J Med       Date:  2004-04-05       Impact factor: 4.965

8.  Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy.

Authors:  Helen A Papadaki; Heraklis D Kritikos; Vasilis Valatas; Dimitrios T Boumpas; George D Eliopoulos
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Treatment of anaemia in inflammatory bowel disease with iron sucrose.

Authors:  G Bodemar; S Kechagias; S Almer; B G Danielson
Journal:  Scand J Gastroenterol       Date:  2004-05       Impact factor: 2.423

10.  The effect of infliximab on extraintestinal manifestations of Crohn's disease.

Authors:  Ilana Kaufman; Dan Caspi; Dror Yeshurun; Iris Dotan; Michael Yaron; Ori Elkayam
Journal:  Rheumatol Int       Date:  2004-08-12       Impact factor: 2.631

View more
  1 in total

1.  Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease.

Authors:  Miranda C E Lomer; William B Cook; Hamid Jan B Jan-Mohamed; Carol Hutchinson; Ding Yong Liu; Robert C Hider; Jonathan J Powell
Journal:  Br J Nutr       Date:  2011-12-09       Impact factor: 3.718

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.